1. Home
  2. NUVL vs HUBS Comparison

NUVL vs HUBS Comparison

Compare NUVL & HUBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$110.87

Market Cap

8.7B

Sector

Health Care

ML Signal

HOLD

Logo HubSpot Inc.

HUBS

HubSpot Inc.

HOLD

Current Price

$221.19

Market Cap

10.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
HUBS
Founded
2017
2005
Country
United States
United States
Employees
228
9021
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
8.7B
10.2B
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
NUVL
HUBS
Price
$110.87
$221.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
16
32
Target Price
$134.75
$435.19
AVG Volume (30 Days)
454.3K
1.9M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
855.56
EPS
N/A
0.62
Revenue
N/A
$375,612,000.00
Revenue This Year
N/A
$20.46
Revenue Next Year
$1,239.49
$16.01
P/E Ratio
N/A
$319.16
Revenue Growth
N/A
N/A
52 Week Low
$71.14
$173.25
52 Week High
$113.02
$611.00

Technical Indicators

Market Signals
Indicator
NUVL
HUBS
Relative Strength Index (RSI) 64.36 54.90
Support Level $97.99 $209.40
Resistance Level $112.61 $225.58
Average True Range (ATR) 3.54 12.85
MACD 0.84 2.20
Stochastic Oscillator 92.70 91.76

Price Performance

Historical Comparison
NUVL
HUBS

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About HUBS HubSpot Inc.

HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.

Share on Social Networks: